Optimizing Lumefantrine Dosing for Young Children in High-Malaria-Burden Countries Using
Segolene Simeon1, Emma Hughes1, Erika Wallender2
1Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA.
Insights
Adjusted artemether-lumefantrine dosing for children under 5 significantly improves malaria treatment outcomes. Modified regimens, especially for malnourished children, increase drug efficacy and reduce treatment failure rates.
Area of Science:
- Pharmacokinetics and Pharmacodynamics
- Global Health
- Pediatric Infectious Diseases
Background:
- Artemether-lumefantrine is a primary treatment for uncomplicated malaria, with dosing guided by World Health Organization (WHO) weight bands.
- Children, particularly those who are underweight, are susceptible to underdosing with standard weight-band regimens.
- Suboptimal dosing increases the risk of malaria treatment failure and the development of drug resistance.
Purpose of the Study:
- To evaluate the impact of adjusted artemether-lumefantrine dosing strategies on achieving therapeutic lumefantrine concentrations and preventing reinfection in children under 5.
- To compare the efficacy of WHO-recommended dosing against alternative regimens, including extended, increased, intensified, and weight-for-age based dosing for malnourished children.
Main Methods:
- Nutritional data from 372,363 children (<5 years) in 25 high-malaria-burden countries were analyzed using Demographic and Health Surveys.
- A population pharmacokinetic-pharmacodynamic model simulated the achievement of day 7 lumefantrine concentrations (≥200 ng/mL) and 42-day malaria-free status.
- Simulations included WHO standard dosing, extended, increased, intensified regimens, and an alternative method for malnourished children based on expected weight for age.
Main Results:
- Standard WHO dosing achieved target lumefantrine levels in 75% of children and 42-day malaria freedom in 77%.
- The alternative dosing method increased target level achievement by 5%; combined with extended regimen, it boosted levels to 97%.
- The combination of alternative and extended dosing resulted in 88% of children remaining malaria-free for 42 days.
Conclusions:
- Current weight-band dosing of artemether-lumefantrine is inadequate for young and underweight children, leading to suboptimal therapeutic drug levels.
- Adjusted dosing strategies, particularly extended regimens for malnourished children based on expected weight for age, significantly improve treatment outcomes.
- Further clinical trials are warranted to validate extended dosing regimens tailored to the nutritional status of children in malaria-endemic regions.
Background:
Artemether-lumefantrine is the most widely used treatment for uncomplicated malaria and it is dosed based on weight bands according to World Health Organization (WHO) guidelines. However, children are vulnerable to underdosing. Inadequate dosing can lead to treatment failure and drug resistance.
Methods:
Nutritional parameters for 372 363 children <5 years old in 25 high-malaria-burden countries were acquired from the Demographic and Health Surveys program. Prevalence of attaining day 7 lumefantrine concentrations ≥200 ng/mL and remaining reinfection free for 42 days were evaluated using a simulation-based approach with a population pharmacokinetic-pharmacodynamic model. Besides the WHO-recommended lumefantrine dosing regimen (twice daily for 3 days), we explored 3 adjusted regimens: extended (2 extra days of dosing), increased (1 extra 120-mg tablet per dose), and intensified (thrice daily for 3 days). We also explored an alternative method dosing malnourished children based on expected weight for age.
Results:
We estimated that 75% of children reached the 200 ng/mL lumefantrine threshold and 77% were malaria free for 42 days when using WHO treatment guidelines. By switching to the alternative dosing method, 5% more children achieved target lumefantrine levels; 22% more achieved the target using the alternative dosing and the extended regimen. With combined alternative plus extended dosing, 97% of children reached 200 ng/mL lumefantrine and 88% were malaria free for 42 days.
Conclusions:
This study highlights the inadequacies of weight-based lumefantrine dosing for young and underweight children and supports the need of clinical trials using extended dosing based on expected weight in malnourished children.
More Related Videos
05:28Standard Membrane Feeding Assay for the Detection of Plasmodium falciparum Infection in Anopheles Mosquito Vectors
Published on: May 12, 2022
09:13Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases
Published on: November 22, 2024
Related Concept Videos
01:21Factors Affecting Drug Response: Overview
01:12Analysis of Population Pharmacokinetic Data
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
01:26Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
01:11Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:19Nonlinear Pharmacokinetics: Overview
Nonlinearity can arise due to the saturation of plasma protein-binding or...